5t The 1 International Moxifloxacin symposium took place in Berlin Germany February 18 - 20,1999. The purpose of this meeting was to introduce the medical and scientific communities to this exciting new fluoroquinolone and to define its role in the management of respiratory tract infections. The fluoroquinolones as a class are an important part of our therapeutic armamentarium and moxi floxacin is a unique addition to this class of compounds. This symposium brought together physician/scientists from around the world to present and discuss the moxifloxacin data. The information from this important meeting are presented in these proceedings and are organized under the following headings: Part I Antimicrobial chemotherapy Part II Pre-clinical microbiology Part III Pharmacology Part IV Clinical needs in the millennium Part V Round table discussion The modifications to the basic quinolone structure resulting in moxifloxacin have produced a drug with unique in vitro, and pharmacokinetic/pharmaco dynamic properties. The drug has a very broad spectrum of antimicrobial activity, is well absorbed and can be taken only once daily. Its profile makes it an excellent therapeutic option for many types of respiratory tract infections. It is hoped that our clinical and laboratory colleagues will be as excited by this data as we are and we look forward to further work with this unique and interesting compound.

to the Symposium

1 - Antimicrobial Chemotherapy
Antimicrobial Chemotherapy - Today
Antimicrobial Chemotherapy - Tomorrow
PART2-Pre-clinical
Pre-clinical Microbiology - Streptococcus Pneumoniae
Pre-clinical Microbiology - Gram-positive Cocci
Pre-clinical Microbiology - Atypical Organisms
Pre-clinical Microbiology - Summary I
Pre-clinical Microbiology - Mycobacteria
In-vitro Activity of Moxifloxacin [Bay 12-8039], an 8-methoxy Quinolone, Compared to Other Fluoroquinolones Against Anaerobic Bacteria
Pre-clinical Microbiology - Fastidious Gram-negative Bacteria
Pre-clinical Microbiology - Respiratory Tract Infections Susceptibility Survey - USA
Pre-clinical Microbiology - Respiratory Tract Infections Susceptibility Survey - Europe
Pre-clinical Microbiology - Respiratory Tract Infections Susceptibility Survey - Japan
Mechanisms of Fluoroquinolone Action and Resistance
Pre-clinical Microbiology - Summary II
3 - Pharmacology
Pharmacokinetics and Pharmacodynamics of Antimicrobials
Mini-Reviews - Pharmacokinetics/Pharmacodynamics (PK/PD)
In vitro Models as Predictors of the Antimicrobial Effect of Moxifloxacin and Other Fluoroquinolones
In vitro Models of Infection - Pharmacokinetic/Pharmacodynamic Correlates
Animal Model Experiences with Moxifloxacin
Current Thinking About Pharmacokinetics and Pharmacodynamics of Antimicrobials
Pharmacology of Moxifloxacin - Absorption, Distribution, Metabolism and Excretion
Antimicrobial Drug-Drug Interations - Focus on Fluoroquinolones
Pharmacology - Tissue Distribution
Fluoroquinolones Phototoxicity - Moxifloxacin in Context
Fluoroquinolone Safety and Tolerability
4 - Clinical Needs in the Millenium
Clinical Needs in the Millenium - Community Acquired Pneumonia
Clinical Needs in the Millenium - Pneumonia - The Role of Moxifloxacin
Clinical Needs in the Millenium - Acute Exacerbations of Chronic Bronchitis
Clinical Needs in the Millenium - Acute Exacerbations of Chronic Bronchitis - The Role of Moxifloxacin
Clinical Needs in the Millenium - Rhinosinusitis
Clinical Needs in the Millenium - Rhinosinusitis - The Role of Moxifloxacin
Discussion on Clinical Needs in the Millenium
5 - Round Table Discussion
Round Table Discussion - Introduction
Round Table Discussion - Hospital Issues
Round Table Discussion - Community Issues.